MarketInOut Stock Screener Log In | Sign Up

Alumis Inc

NASDAQ • Healthcare • Biotechnology • Quote as of 11/13/2026
Alumis Inc stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization727 mln
Float95.39 mln
Earnings Date03/25/2027

Piotroski F-Score

2 / 9
Weak

Beneish M-Score

-2.9
Likely reliable

Relative Strength

13 / 100
Significantly lagging

Debt / Equity

0.09
Debt-free

Pre-Tax Margin

-5,869%
Severely loss-making

ROE

-102
Deeply negative

Business Description

Alumis Inc. is a drug development company based in South San Francisco, California, working to bring new treatments to patients with autoimmune and inflammatory conditions. Its leading drug candidate targets a protein called TYK2, which plays a key role in driving diseases such as plaque psoriasis and lupus, while a second compound in early-stage testing aims to address inflammation in the brain and nervous system. The company is also developing treatments for thyroid eye disease and broader immune system disorders. Founded in 2021 under the name Esker Therapeutics, Alumis is working to build a focused portfolio of medicines in areas where patients still have limited options.

Key Fundamentals

EPS-3.53
ROE-102
RPS0.06
ROIC-366
ROA-80.59
EBITDA, mln-421
EV / EBITDA-0.78
EV / EBIT-0.77
Revenue, mln7.24
EV / Revenue45.42

Quote Details

Last 5.60
Change -0.53 (-8.65%)
Open 6.04
Volume 1,492,039
Turnover 8,355,418
Average Volume 1,826,404

Financial Ratios

Pre-Tax Profit Margin-5,869
Leverage Ratio1.29
Current Ratio5.57
Price / Book1.92
Price / Tangible Book1.96
Debt / Equity0.09
Price / Sales93.33

Financial Strength

Altman Z-Score-1.55
Piotroski F-Score 2 / 9
Beneish M-Score-2.9
Short Ratio5.28
Short % of Float14.16

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -7.13% 15 / 100   
1 Month -11.25% 27 / 100   
2 Months -79.66% 3 / 100   
6 Months -75.51% 7 / 100   
1 Year 6.87% 62 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog